Background/Aims/Objective: This study compared data on the use of prenatal tests offered to pregnant women in Israel as reported in a national survey conducted by the Israel Center for Disease Control in 2001 to data from 2010. Methods: Mothers of newborns were interviewed 8-72 h after delivery in 29 maternity wards in Israel on May 31, 2010. Results: A total of 768 women were interviewed, 569 (72.3%) were Jewish and 197 (25.7%) were Arabs. Nuchal translucency screening and early ultrasound level 2 were significantly more frequently done in both Jewish and Arab women in 2010 than in 2001. The use of the biochemical triple marker test and amniocentesis did not change. The increased rate of nuchal translucency screening and early ultrasound level 2 was significantly higher among the Jewish women compared to the Arabs (21.5 and 28.0% vs. 2.9 and 13.7% in 2001; 62.0 and 65.6% vs. 30.1 and 30.9% in 2010, respectively). The rates of amniocentesis in the Jewish women aged ≥35 years were 47.6 and 47.5% in 2001 and 2010, respectively; they are significantly higher than among the Arabs (18.5 and 28.5%, respectively). The factors associated with making more use of different prenatal tests were: secularity, a higher income, and supplementary medical insurance for the Jewish women, and supplementary medical insurance and printed information on prenatal testing for the Arabs. Conclusions: The prenatal testing rates have risen over the last decade in both population groups, but there are still significant gaps. We suggest that public funding of additional prenatal tests may increase their use in both population groups.

1.
Sher C, Romano-Zelekha O, Green SM, Shohat T: Factor affecting performance of prenatal genetic testing by Israeli Jewish women. Am J Med Genet 2003;120A:418-422.
2.
Sher C, Romano Zelekha O, Green SM, Shohat T: Utilization of prenatal genetic testing by Israeli Moslem women: a national survey. Clin Genet 2004;65:278-283.
3.
Department of Community Genetics, Israel Ministry of Health: Genetic screening test (in Hebrew). Communication No. 7/13, February 27, 2013.
4.
Muhsen K, Na'amnah W, Lesser Y, Volovik I, Cohen D, Shohat T: Determinates of underutilization of amniocentesis among Israeli Arab women. Prenat Diagn 2010;30:138-143.
5.
Department of Community Genetics, Israel Ministry of Health: Down syndrome in Israel (in Hebrew). Annual Report 2010-2011.
6.
Jaber L, Dolfin T, Shohat T, Halpern GJ, Reish O, Fejgin M: Prenatal diagnosis for detecting congenital malformation: acceptance among Israeli Arab women. Isr Med Assoc J 2000;2:346-350.
7.
Zlotogora J, Israeli A: A comprehensive screening program for cystic fibrosis. Isr Med Assoc J 2009;11:555-557.
8.
Sukenik-Halevy R, Leil-Zoabi UA, Peled-Perez L, Zlotogora J, Allon-Shalev S: Compliance for genetic screening in the Arab population in Israel. Isr Med Assoc J 2012;14:538-542.
9.
Zlotogora J, Haklai Z, Levental A: Utilization of prenatal diagnosis and termination of pregnancies for the prevention of Down syndrome in Israel. Isr Med Assoc J 2007;9:600-602.
10.
Remennick L: The quest for the perfect baby: why do Israeli women seek prenatal genetic testing? Sociol Health Illn 2006;28:21-53.
11.
Shoham-Vardi, Weiner N, Weitzman D, Levcovich A: Termination of pregnancy: attitude and behavior of women in a traditional society. Prenat Diagn 2004;24:869-875.
12.
Lesser Y, Rabinowitz J: Elective amniocentesis in low-risk pregnancies: decision making in the era of information and uncertainty. Am J Pub Health 2001;91:639-641.
13.
Fuller CA, Gallagher R: What's happening: perceived benefits and barriers of prenatal care in low-income women. J Am Acad Nurse Pract 1999;11:527-532.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.